Company Insights

HSDT customer relationships

Explore interactive graphBrowse insights index
HSDT customer relationship map

Helius Medical Technologies (HSDT) — commercial relationships that will determine the PoNS growth curve

Thesis: Helius Medical Technologies sells a single core product, the Portable Neuromodulation Stimulator (PoNS), and monetizes through device sales, mouthpiece consumables, clinic services and targeted contracts with government purchasers and payers; near-term value hinges on reimbursement adoption, VA/federal channel wins and the company’s ability to convert limited early demand into scale. Learn more about relationship-level signals and commercial constraints at https://nullexposure.com/.

How Helius actually makes money — the commercial model in plain English

Helius is a small, hardware-led medical device company that sells the PoNS controller and replaceable mouthpiece directly to patients, clinics and through an e-commerce channel, while pursuing insurance and government reimbursement to replace a largely self-pay base. The company established U.S. list pricing (controller + mouthpiece) and has started to land federal channels—PoNS is on the VA Federal Supply Schedule and DOD contracts—which convert higher-ticket one-time device sales into a predictable sales channel. For 2024 Helius recorded roughly $0.5 million in product revenue; profitability depends on expanding payer coverage and reducing customer concentration. Visit https://nullexposure.com/ for deeper customer relationship intelligence.

Commercial posture and operating constraints that matter to investors

  • Contracting posture: Evidence shows mixed contract durations — the PoNS therapy itself is a short-term (14-week) treatment, sales transactions are often point-in-time, but the company also executes longer exclusivity and distribution agreements (initial terms through 2027 with renewable extensions). The VA/Federal Supply Schedule relationship functions as a framework contract that enables recurring federal sales.
  • Counterparty mix and criticality: The company serves a large number of individual patients directly while pursuing government payers and large insurers, and internal disclosures mark reimbursement coverage as critical to market acceptance. One customer historically represented a very high percentage of receivables, underscoring client concentration risk.
  • Geography and maturity: Commercialization is North America-first (Canada commercialization since 2019; U.S. prescriptions from 2022) with approvals in Australia and a paused EU effort; the business remains an early commercial venture with limited revenue traction so far.
  • Product and segment concentration: Helius’ revenue is essentially single-product driven (hardware and consumable mouthpieces) and service-driven therapy programs that accompany device use; this concentrates execution risk on manufacturing, regulatory compliance and clinical adoption.
  • Material financial signals: The company shows negative operating margins and concentrated receivables; coverage decisions from CMS and major commercial payers are the principal revenue levers.

What every disclosed relationship says about commercial strategy

Below are the relationships surfaced in public materials and what each one signals about Helius’ route to scale.

United Healthcare (UNH)

A press release reported that Aetna authorized an out-of-network claim price of $18,350 for the PoNS device and that Aetna joins Anthem and United as payers providing PoNS reimbursement, which signals widening commercial payer acceptance in FY2025. Source: company press release distributed via Yahoo Finance (March 10, 2026).

Anthem (ANTM)

Anthem is named alongside United and Aetna as a payer providing PoNS reimbursement, marking three major commercial insurers offering coverage and improving the economics of selling PoNS into insured patient flows in FY2025. Source: company press release distributed via Yahoo Finance (March 10, 2026).

Aetna Healthcare (CVS)

Helius announced that Aetna Healthcare authorized a claim for payment for the PoNS device, a substantive commercial milestone for PoNS reimbursement and patient access in FY2025. Source: company press release distributed via Yahoo Finance (March 10, 2026).

PayPal (PYPL)

In the Q3 2025 earnings call transcript (hsdt-2025q3), the company’s prepared remarks referenced PayPal in the context of a broader technology/ecosystem discussion — specifically noting PayPal’s integration for stablecoin payments on Solana — indicating Helius’ earnings materials included cross-industry references though not directly linked to core PoNS sales (Q3 2025 earnings call, March 8, 2026). Source: HSDT Q3 2025 earnings call transcript (hsdt-2025q3-earnings-call).

Stripe (STRIP)

The same Q3 2025 earnings call includes a line mentioning Stripe alongside PayPal as payment integration partners in the Solana-focused commentary, showing the company referenced modern payment rails in investor communications (Q3 2025 earnings call, March 8, 2026). Source: HSDT Q3 2025 earnings call transcript (hsdt-2025q3-earnings-call).

Apollo (APO)

Apollo is cited in the Q3 2025 earnings call as an example in a broader discussion about emerging real-world asset ecosystems, reflecting the transcript’s use of large financial firms as comparators in strategic commentary (Q3 2025 earnings call, March 8, 2026). Source: HSDT Q3 2025 earnings call transcript (hsdt-2025q3-earnings-call).

BlackRock (BLK)

BlackRock is named in the earnings call as another participant in real-world asset tokenization examples, highlighting the company’s attempt to contextualize market opportunity using major asset managers in Q3 2025 investor commentary (Q3 2025 earnings call, March 8, 2026). Source: HSDT Q3 2025 earnings call transcript (hsdt-2025q3-earnings-call).

Franklin Templeton (BEN)

Franklin Templeton appears alongside BlackRock and Apollo in the Q3 2025 call excerpt, again included in broader market examples rather than as an operational customer of PoNS (Q3 2025 earnings call, March 8, 2026). Source: HSDT Q3 2025 earnings call transcript (hsdt-2025q3-earnings-call).

(If you want a consolidated, relationship-prioritized view with quantified exposure and contract terms, see the company-level intelligence hub at https://nullexposure.com/.)

Risk versus runway — the investment checklist

  • Upside: Assignment of HCPCS codes and public payer placements on VA/DOD federal schedules plus recent commercial insurer actions (Aetna/Anthem/United) are clear accelerators for adoption and reimbursement economics.
  • Risks: Severe revenue concentration, early-stage commercial traction (roughly $0.5M revenue in 2024), negative operating margins and dependence on payer policy decisions create downside sensitivity to reimbursement and physician adoption.
  • Operational focus: Scaling requires expanding clinic throughput, converting federal placements into repeatable orders, and reducing per-sale customer concentration while maintaining manufacturing and regulatory compliance.

Conclusion and next steps

For investors and operators, Helius is a single-product, reimbursement-dependent commercial roll-out: payor wins translate directly into demand and valuation uplift; conversely, coverage reversals or weak clinic adoption compress upside fast. For structured insight into counterparty contracts and concentration analytics, visit https://nullexposure.com/ to see the relationship signals that matter. Final note: monitor payer coverage trends and VA/DOD procurement velocity as the decisive near-term catalysts for revenue scaling — learn more at https://nullexposure.com/.